Future Retirement Success
  • Politics
  • Business
  • Investing
  • Stocks
  • Politics
  • Business
  • Investing
  • Stocks

Future Retirement Success

Business

PPE Medpro hits back in £122m DHSC court case, blaming government ‘chaos’ during Covid procurement

by June 12, 2025
June 12, 2025
PPE Medpro hits back in £122m DHSC court case, blaming government ‘chaos’ during Covid procurement

PPE Medpro, the company linked to Conservative peer Michelle Mone, has launched a robust defence in its £122 million High Court battle with the Department of Health and Social Care (DHSC), accusing the government of “buyer’s remorse” and “chaotic mismanagement” during the early stages of the Covid-19 pandemic.

In its opening submissions, PPE Medpro claims the government is unfairly targeting the firm to deflect attention from its own errors during the emergency procurement frenzy. The company’s legal team argues that DHSC approved the surgical gowns it supplied, despite knowing full well that they did not bear CE markings with a notified body (NB) number—technical requirements usually mandatory under medical device regulations, but waived under emergency rules at the time.

The defence pivots on the claim that PPE Medpro offered the gowns under what was known as an “equivalent technical solution,” a route explicitly permitted by the UK government’s own guidance during the pandemic. The firm says DHSC’s technical assurance team signed off on this basis and never indicated that a formal derogation or notified body certification was necessary prior to contract approval.

“Gowns have been approved by Technical!” an email from a DHSC official to PPE Medpro read at the time, indicating departmental consent. This, the company argues, confirms that the government accepted the technical and regulatory basis of the order. PPE Medpro also asserts that the gown packaging was clearly marked and that DHSC—or its logistics agent Uniserve—had the opportunity to inspect the goods upon collection in China but failed to do so .

The government has alleged that the gowns were unfit for use, citing later sterility tests in the UK. But PPE Medpro has dismissed those results as irrelevant, arguing that the tests were conducted on expired or poorly stored items long after delivery—potentially contaminating the samples. The firm adds that independent experts agreed the unusual mix of microorganisms found in the tested gowns pointed to contamination during storage and transport, not manufacturing .

In a striking accusation, PPE Medpro claims it has been singled out among hundreds of Covid suppliers, possibly due to the high-profile connections of its backers and the perception of its financial capacity to pay back funds. The firm also points to a wider “campaign of pressure,” alleging that the civil case is running in parallel with a “never-ending” National Crime Agency investigation that is yet to yield charges.

“The DHSC is attempting to retroactively rewrite the rules of engagement,” the submission argues. “This is a textbook case of a government seeking to claw back money from a contract it regrets, despite the fact it knew exactly what it was buying.”

The legal row centres around a £122 million order for 25 million sterile surgical gowns, delivered in 2020. The DHSC rejected the gowns months later, citing concerns over CE marking and sterility—despite having passed them through its technical assurance process and cleared the contract through internal approval committees, including sign-off by then-senior civil servant David Williams .

The outcome of the case could have far-reaching implications for pandemic-era procurement disputes and future government use of emergency powers. With billions of pounds’ worth of PPE still unused in storage, the trial is being closely watched as a bellwether for accountability.

The case continues.

Read more:
PPE Medpro hits back in £122m DHSC court case, blaming government ‘chaos’ during Covid procurement

0
FacebookTwitterGoogle +Pinterest
previous post
Taiwan ramps up coast guard and military readiness in face of Beijing’s ‘gray zone’ warfare
next post
What Might a Libertarian Do as President?

You may also like

Coffee pod ads banned by UK watchdog over...

April 30, 2025

Vodafone credit card size 5G network could eventually...

February 23, 2023

UK reaches key milestone with one million electric...

February 5, 2024

Just Eat snapped up at a fraction of...

February 24, 2025

Raspberry Pi Shares Surge on London Debut, Sparking...

June 12, 2024

Jeremy Clarkson’s Hawkstone beer taps into global growth...

April 2, 2025

Secrets of Success: Susie Stubbs, Founder of Totter...

January 26, 2024

SMEs are at risk of losing a David...

March 30, 2023

Staff at UK aviation regulator vote to strike...

August 23, 2023

Independent Scottish organic whisky distillery Nc’nean secures new...

November 15, 2023

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free

    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • ‘All-in’: GOP lawmakers divided on US involvement as Trump pushes Iran for diplomatic end

      June 14, 2025
    • Democratic lawmakers criticize Israel’s defensive strikes against Iran’s nuclear sites

      June 13, 2025
    • Israel’s drone strikes in Iran show why US must halt China’s land grab here: experts

      June 13, 2025
    • Biden-appointed judge thwarts Trump’s attempt to clean house at consumer safety agency

      June 13, 2025
    • Nearly half of Americans back Israeli airstrikes on Iran, poll shows

      June 13, 2025
    • Iran threatens to hit US bases in the Middle East: What is the threat level?

      June 13, 2025

    Categories

    • Business (8,205)
    • Investing (2,035)
    • Politics (15,646)
    • Stocks (3,147)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: futureretirementsuccess.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 futureretirementsuccess.com | All Rights Reserved